Cargando…
The Cancer-Immunity Cycle in Multiple Myeloma
Multiple myeloma is a plasma cell malignancy that primarily affects the elderly. The global burden of multiple myeloma is increasing in many countries due to an aging population. Despite recent advances in therapy, myeloma remains an incurable disease, highlighting the pressing need for new therapie...
Autores principales: | Casey, Mika, Nakamura, Kyohei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8291851/ https://www.ncbi.nlm.nih.gov/pubmed/34295843 http://dx.doi.org/10.2147/ITT.S305432 |
Ejemplares similares
-
Anticancer activity of a Gold(I) phosphine thioredoxin reductase inhibitor in multiple myeloma
por: Sze, Jun Hui, et al.
Publicado: (2019) -
Immunotherapy for Multiple Myeloma
por: Tamura, Hideto, et al.
Publicado: (2019) -
The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017) -
Boosting Immunity against Multiple Myeloma
por: Lopes, Raquel, et al.
Publicado: (2021) -
Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA
por: Casey, Mika, et al.
Publicado: (2022)